On the chart you can see the default numbers in dynamics for Thermo Fisher Scientific Inc. (TMO). Companys revenue shows the average of 10465.227 M which is 0.166 % gowth. The average gross profit for the whole period is 4712.713 M which is 0.176 %. The average gross profit ratio is 0.431 %. The net income growth for the company last year performance is -0.137 % which equals 6.976 % % on average for the whole company history.,
Diving into the fiscal trajectory of Thermo Fisher Scientific Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.016. In the realm of current assets, TMO clocks in at 24589 in the reporting currency. A significant portion of these assets, precisely 8077, is held in cash and short-term investments. This segment shows a change of -0.052% when juxtaposed with last year's data. The debt profile of the company shows a total long-term debt of 31308 in the reporting currency. This figure signifies a year_over_year change of 0.012%. Shareholder value, as depicted by the total shareholder equity, is valued at 46724 in the reporting currency. The year over year change in this aspect is 0.062%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 8221, with an inventory valuation of 5088, and goodwill valued at 44020, if any. The total intangible assets, if present, are valued at 16670. Account payables and short-term debt are 2872 and 3609, respectively. The total debt is 34917, with a net debt of 26840. Other current liabilities amount to 4842, adding to the total liabilities of 51884. Lastly, the referred stock is valued at 0, if it exists.
The financial landscape of Thermo Fisher Scientific Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.002. The company recently extended its share capital by issuing 0, marking a difference of 0.227 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -5142000000.000 in the reporting currency. This is a shift of 1.382 from the previous year. In the same period, the company recorded 3406, -90, and -155, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -523 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 56, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Thermo Fisher Scientific Inc.'s revenue saw a change of -0.046% compared with the previous period. The gross profit of TMO is reported to be 15224. The company's operating expenses are 7906, showing a change of -28.082% from the last year. The expenses for depreciation and amortization are 3406, which is a -0.070% change from the last accounting period. Operating expenses are reported to be 7906, which shows a -28.082% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.128% year-over-year growth. The operating income is 7318, which shows a -0.128% change when compared to the previous year. The change in the net income is -0.137%. The net income for the last year was 5995.
